physIQ receives $500000 for its AI healthcare solutions – ITIJ

Founded by Gary Conkright, an alumnus of Purdues College of Engineering, physIQ (which is incidentally a Purdue University-affiliated company) applies AI to real-time physiological data from wearable sensors in order to develop solutions that will improve healthcare outcomes.

The money that physIQ has received is from Purdue Research FoundationsFoundry Investment Fund, which was established in 2014 through a partnership between Purdue research Foundations and Cook Medical. The goal of the fund is to add critical capital for the transition from the discovery of a promising technology to founding a viable life sciences company. In the past five years, the Foundry Investment Fund has invested nearly $5 million in 13 companies.

The Foundry Investment Fund plays an important role in attracting interest in Purdue-affiliated life sciences companies, said John Hanak, Managing Director ofPurdue Ventures. Gary Conkrights team at physIQ offers a great example of the kinds of technology and products that align perfectly with the goals of the fund.

Commenting on the funding, Conkright noted that, one of the many exciting factors of the collaboration is that it facilitates a closer alignment with some of Purdues experts. One specific example is the direct collaboration with the school of biomedical engineering, which will accelerate physIQs work in areas in which they excel. In tandem, we are providing real-world use cases to the schools research efforts, he said.

This investment is an incredible show of support and confidence in our technology and our vision from the Purdue Research Foundation, Conkright added. The Foundations support will help us continue to lead the way in changing how healthcare is developed and delivered through FDA-cleared physiology analytics.

View post:
physIQ receives $500000 for its AI healthcare solutions - ITIJ

Study advances the understanding of capillary regression – News-Medical.net

Many diseases arise from abnormalities in our capillaries, tiny exquisitely branching blood vessel networks that play a critical role in tissue health. Researchers have learned a lot about the molecular communication underlying capillary formation and growth, but much less is understood about what causes these critical regulators of normal tissue function to collapse and disappear.

"Capillary regression (loss) is an underappreciated, yet profound, feature of many diseases, especially those affecting organs requiring a lot of oxygen to work properly," said George Davis, MD PhD, professor of molecular pharmacology and physiology at the University of South Florida Health (USF Health) Morsani College of Medicine, Tampa, Fla.

"If we know how blood vessels are altered or begin to break down we should be able to fix it pharmacologically," said Dr. Davis, a member of the USF Health Heart Institute.

A team led by Dr. Davis advanced the understanding of how capillaries regress in a study published Dec. 19 in the American Heart Association journal Arteriosclerosis, Thrombosis, and Vascular Biology. The USF Health researchers worked with the laboratory of Courtney Griffin, PhD, at Oklahoma Medical Research Foundation.

The researchers discovered that three major proinflammatory mediators - interlukin-1 beta (IL-1), tumor necrosis factor alpha (TNF) and thrombin - individually and especially when combined, directly drive capillary regression (loss) known to occur in diseases such as hypertension, diabetes, cardiovascular diseases, neurodegenerative diseases and malignant cancer. They also identified combinations of drugs - neutralizing antibodies to specifically block IL-1 and TNF, or combinations of pharmacologic inhibitors - that significantly interfered with capillary regression.

Capillaries, our body's tiniest and most abundant blood vessels, connect arteries with veins and exchange oxygen, nutrients and waste between the bloodstream and tissues throughout the body. The Davis laboratory grows three-dimensional human "blood vessel networks in a dish" under defined, serum-free conditions to delve into the complexity of how capillaries take shape to sustain healthy tissues. Lately, his team has begun applying what they've learned using this innovative in vitro model to attack, and possibly protect against, diseases.

For this study the researchers cultured two types of human cells: endothelial cells, which line the inner surface of capillaries, and pericytes, which are recruited to fortify the outer surface of the endothelial-lined tubes. Cross-communication between these cells controls how the blood vessel networks emerge, branch and stabilize. Macrophages, a type of immune cell, were activated in the cell culture media to simulate a tissue-injury environment highly conducive to capillary regression.

Among the key study findings:

- Macrophage-derived molecules IL-1 and TNF, combined with thrombin, selectively cause endothelial-lined capillary tube networks to regress; however, pericytes continue to proliferate around the degenerating capillaries. Why the pericytes are spared remains an intriguing question to be answered, but Dr. Davis suggests these more resilient cells may be left behind to help repair tissue damaged by inflammation.

- IL-1 and TNF, combined with thrombin, induce a unique set of molecular signals contributing to the loss of blood vessels. This "capillary regression signaling signature" is opposite of the physiological pathways previously identified by Dr. Davis and others as characterizing capillary formation and growth.

- Certain drug combinations (two were identified by the researchers) can block the capillary loss promoted by IL-1, TNF and thrombin.

The USF Health researchers found several other proinflammatory molecules that promoted capillary loss, but none proved as powerful as IL-1, TNF and thrombin, especially when all three were combined.

Antibodies to counteract the effects of IL-1 and TNF are already used to treat patients with some inflammatory diseases, including atherosclerosis, rheumatoid arthritis, and Crohn's disease. And physicians prescribe direct thrombin inhibitors for certain patients with atrial fibrillation, deep vein thrombosis and pulmonary embolism.

These drugs are out there and they work. Our data suggests that, if combined, they may actually prevent vessel breakdown (earlier in the disease process) and improve outcomes."

Dr. George Davis, a member of the USF Health Heart Institute

The USF Health team plans to investigate how abnormal capillary response may influence the loss of cells and tissues specific to disease states like sepsis, ischemic heart disease and stroke. Their model of 3D blood vessel networks can also be easily used to screen more potential drug candidates, Dr. Davis said. "We've identified some promising (existing) drugs to rescue capillary regression -- but there may be more therapeutic opportunities."

Source:

Journal reference:

Koller, G.M., et al. (2019) Proinflammatory Mediators, IL (Interleukin)-1, TNF (Tumor Necrosis Factor) , and Thrombin Directly Induce Capillary Tube Regression. Arteriosclerosis, Thrombosis, and Vascular Biology. doi.org/10.1161/ATVBAHA.119.313536.

See the original post:
Study advances the understanding of capillary regression - News-Medical.net

‘Like 5’4 and a complete badass’ – The Daily Evergreen

In the Physical Education Building, junior and black beltAndrea Barcenas teaches karate, boxing and other forms of self-defense.

Barcenas practicesKaratedo Doshinkan, which she said pulls the best aspects of other martial artsforms and incorporate it into one. While she also teaches judo, Kyokushinkarate, Muay Thai and boxing in her class, Karatedo Doshinkan is what shesbeen training in for 15 years.

I try to make [the class] as fun and incorporating aspossible, Barcenas said. One thing I didnt like when I was younger was, ofcourse, a 6-year-old doesnt want to stand for three hours. But you learn, itsdiscipline. So yeah its tough, but its also fun.

Barcenas has been involved in martial arts since she wasfour, encouraged by her father, who did martial arts when he was a child.

Barcenas said she didnt like karate until she turned 13,where she started learning more about the outside world and saw its value.

One time my sister and me were walking home from schooland for some reason someone decided to choke her, and he said it was for fun,Barcenas said. And I was like Well, why dont you do that to me since its fun,and then this is, like, elementary [school] I grabbed him and I threw himover my back, on the pavement in front of all of the security guards, all ofthe teachers, all of the parents, and then I just grabbed [my sisters] handand walked away.

Right now Barcenas studies mechatronics robotics andautomation engineering, which WSU does not offer as a major but does providethe foundations for, Barcenas said. After college, Barcenas said she wants towork in animatronics, robotics or programming.

She said she is still considering opening a dojo butbesides needing the permission of her sensei, she said she doesnt think shesat that level yet.

Even after I got [my black belt, and] after 12 years itstill wasnt enough, but I think everyones definition of enough is different,Barcenas said. I feel like my bar is all the way up here, so, unrealisticallyhigh expectations.

Ive been in situations where Ive had a gun held to my face. I never want that to happen again.

Jillian Lenicka, WSUfreshman nutrition and exercise physiology major and student of Barcenas,said she is an energetic and passionate person when it comes to self-defense.

Computer science major and president of Judo Club MatthewMolitor said he first met Barcenas while she was doing a demonstration at amartial arts symposium, where she was breaking wooden boards and cinder blocks.

I was blown away by that because she was unassuming, like 54, and a complete badass,Molitor said. It kind of gave me a respect for karate.

Barcenas said she sees karate as a spiritual activity,something that shes incorporated into her life mentally, spiritually,physically, even if she doesnt do it every day.

Im terrified of the outside world sometimes, thats whyI wanted to learn to protect myself, she said. Because Ive been insituations where Ive had a gun held to my face. I never want that to happenagain.

Barcenas calls self-defense a security blanket, andsaid its important to learn to protect oneself if a dangerous situation comesup.

If youre like me and your mind runs at a hundred milesan hour youre always thinking about what could happen, Barcenas said. Inever want to be in that situation again, therefore Ill never let myself getin that situation again. If it happens, theyre not coming out of it.

See more here:
'Like 5'4 and a complete badass' - The Daily Evergreen

MBBS Students scattered magnificence with flower rangoli, know the information – Sahiwal Tv

The tennis garden of King George Medical University was embellished with flowers on the event of Vasant Panchami. A lovely view of gorgeous flowers was being constructed throughout.

Girl college students awoke all through the evening and made a rangoli of flowers, Saraswati Puja was completed within the morning courtyard. After which Medicose fiercely took a selfie in yellow garments.

Vice Chancellor Prof. MLB Bhat paid obeisance to mom Saraswati after performing and worshiping her. The Vice Chancellor advised the scholars in regards to the significance of Vasant Panchami and stated that Vasant Panchami is a pageant of worship of Mother Saraswati, which offers us with data, knowledge, knowledge and fame.

After the Saraswati Pujan, a program of Yajna, Prasad distribution was additionally organized.

->In which all the scholars together with medical college medical doctors, academics, college students of MBBS participated enthusiastically.

On this event, the complete courtyard was embellished with colourful Rangoli by the scholars of MBBS 2018 batch with the contribution of the scholars of MBBS 2019 batch.

The organized group, primarily fashioned by all the scholars of the 2018 batch, contributed to all the enjoyment and enthusiasm in organizing this system.

On this event, Rangoli competitors for the scholars of MBBS 2019 batch was organized by the Department of Physiology, together with Prof. Sunita Tiwari, Head of the Department of Physiology, Dr. Archana Ghilliyal, Acharya, and Professor and Principal of Physiology, Student Welfare, Prof. Narsingh Verma. Gave full contribution and steerage. Along with this, about 80 college students from four groups participated in Rangoli competitors.

Cartoon making competitors, collage making and pot portray competitors have been additionally organized on this event. In the stated program, former Principal of KGMU, Prof. AM Kar, inspired the scholars collaborating in varied competitions and honored the winners of the competitors by giving them prizes.

Link:
MBBS Students scattered magnificence with flower rangoli, know the information - Sahiwal Tv

The heroines STEM: Ten women in science you should know – East Bay Times

By Lauren Kent | CNN

Science is often considered a male-dominated field.

In fact, according to United Nations data, less than 30% of scientific researchers worldwide are women.

Studies have shown that women are discouraged from, or become less interested in, entering the fields of science, technology, engineering and math (STEM) beginning at a young age. And according to the Pew Research Center, women remain underrepresented in engineering, computer science and physical science.

But despite challenges of gender discrimination and lack of recognition in the scientific community, countless inspiring women in these fields have made historic contributions to science and helped advance understanding of the world around us. Many were not recognized in their own lifetimes, but their achievements have helped generations of female scientists to come.

We all learned about Marie Curie and Jane Goodall, but here are 10 more women in science you should know.

American chemist Alice Ball was the first woman and first African American to receive a masters from the University of Hawaii and went on to become the universitys first female chemistry professor. At just 23 years old, Ball developed a groundbreaking treatment for leprosy a disease which previously had little chance of recovery and forced victims into exile.

Prior to Balls research on leprosy, the best treatment available was chaulmoogra oil, which was difficult for patients to ingest or apply topically and too thick to inject. While working as a research assistant at Kalihi Hospital in Hawaii, Ball developed an easily injectable form of the oil that ultimately saved countless lives and became the best treatment for leprosy until the 1940s.

Unfortunately she died before she was able to publish the findings, and the president of the University of Hawaii attempted to claim the research as his own until Balls former supervisor publicly spoke out that she deserved the credit for the lifesaving injection. It wasnt until the 21st century that her achievements were fully recognized and the governor of Hawaii declared February 29 Alice Ball Day.

Legend has it that British chemist and DNA researcher Rosalind Franklin knew she wanted to be a scientist since she was 15 years old. That dream went on to become a reality when she was offered a prestigious scholarship to Kings College London, where she became an expert in the X-ray crystallography unit.

Franklins research data was the first to demonstrate the basic dimensions of DNA strands and reveal the molecule was in two matching parts, running in opposite directions. Her data was used by James Watson and Francis Crick to get their research on the DNA model across the finish line, and was published separately as supporting data alongside Watson, Crick and Maurice Wilkins research articles in Nature.

Many people in the scientific community argue that Franklin should have been awarded a Nobel Prize alongside Watson, Crick and Maurice Wilkins, who won the 1962 Nobel Prize in Physiology or Medicine for their discoveries concerning the molecular structure of nucleic acids and its significance for information transfer in living material. Unfortunately, Franklin died from ovarian cancer in 1958, just four years before the prize was awarded, even though at the time the organization could have awarded it posthumously.

Dorothy Hodgkin was a British chemist on the cutting edge of X-ray crystallography. In 1964, Hodgkin became the first and only British woman to win the Nobel Prize in Chemistry for her determinations by X-ray techniques of the structures of important biochemical substances.

Throughout her career, she made numerous breakthrough discoveries, including the atomic structure of penicillin, the structure of vitamin B12 and the structure of insulin. Hodgkin also spent decades improving X-ray crystallography techniques, which made it possible for her to complete her innovative research on insulin and improve treatments for diabetes.

She also became the second woman to win the UKs prestigious Order of Merit in 1965. While Hodgin was a professor at Oxford University, she even mentored Prime Minister Margaret Thatcher, who would go on to win the Order of Merit herself.

Grace Hopper was a trailblazing computer programmer who helped develop multiple computer languages and is considered one of the first programmers of the modern computing age.

Armed with a masters degree and PhD in mathematics from Yale, Hopper went on to have an influential career in the private sector and the US Navy. She joined the US Naval Reserve in 1943 to help with the American war effort, and throughout WWII she worked in a prestigious lab responsible for top-secret calculations such as calibrating minesweepers, calculating the ranges of anti-aircraft guns and checking the math behind the creation of the plutonium bomb.

Her career also contributed to modern computer vernacular. While Hopper was developing some of the earliest electromechanical computers MARK I and MARK II she dismantled a malfunctioning computer to find that a dead moth was causing the problem. She became the first person to call computer problems bugs in the system.

American botanist Barbara McClintock was responsible for several groundbreaking discoveries in the field of genetics following her decades-long career studying the genetic structure of maize. McClintock studied how genetic characteristics are passed down through generations, eventually uncovering that some genes could be mobile.

In the 1940s and 1950s, McClintocks research revealed that genetic elements could sometimes move on a chromosome and thus cause nearby genes to activate. But it wasnt until decades later that scientists apart from maize specialists understood and recognized the immense value of her discovery.

McClintock was awarded the National Medal of Science in 1971 and won the Nobel Prize in Physiology or Medicine in 1983 for her discovery of mobile genetic elements, now called transposons.

Austrian physicist Lise Meitner contributed significant advancements to the field of nuclear physics. She was also the first woman to become a physics professor in Germany.

Meitners work on nuclear fission was instrumental in her longtime research collaborator Otto Hahn winning the 1944 Nobel Prize in Chemistry, so much so that many scientists later argued it was unfair for her contributions to not have been recognized equally by the Nobel Committee. Meitner was also an advocate for the peaceful use of atomic energy and flatly refused to work on the Manhattan Project because she strongly opposed using fission to create an atom bomb.

Today, multiple prestigious awards in physics are named in honor of Meitner and she even has a chemical element meitnerium named after her.

NASA astronaut Sally Ride became the first American woman in space, serving as a mission specialist on the space shuttle Challenger in 1983. At 32 years old, she was also the youngest American to ever leave the atmosphere. (She wasnt the first woman in space, though that title belongs to Soviet cosmonaut Valentina Tereshkova.)

After the Challenger disaster in 1986, in which an explosion occurred shortly after takeoff and claimed the lives of seven astronauts, Ride served on the Rogers Commission, which investigated the tragedy. She also helped investigate the space shuttle Columbia disaster in 2003, during which the shuttle disintegrated as it re-entered the atmosphere, making Ride the only person to serve on both investigation commissions.

Ride went on to have an award-winning career as a public servant and as a physics professor at the University of California, San Diego. She also founded Sally Ride Science, an organization that aims to inspire young people in STEM, and she wrote several books about her experience in space to teach kids about science.

Pharmaceutical chemist Tu Youyous discovery of a new malaria treatment has saved millions of lives. Tu, who studied traditional Chinese and herbal medicines, found a reference in ancient medical texts to using sweet wormwood to treat intermittent fevers a symptom of malaria.

Tu and her research team were able to extract a malaria-inhibiting substance called artemisinin (or qinghaosu in Chinese) from wormwood. She even volunteered to be the first human subject to test the substance. Since her discovery of artemisinin in the 1970s, antimalarial drugs based on the substance have saved millions of lives.

Tu is now chief scientist at the China Academy of Traditional Chinese Medicine a position she reached without a medical degree, a PhD, or research training abroad. She won the 2015 Nobel Prize in Physiology or Medicine for her discovery, which has been deemed arguably the most important pharmaceutical intervention in the last half-century by the Lasker Foundation for medical research.

Maria Winkelmann was a pioneer in German astronomy. In 1902, she became the first woman to discover a new comet. Sadly, her husband Gottfried Kirch published the discovery in his own name, and did not publicly reveal her as the true source of the comet discovery until years later.

However, Winkelmann was still widely recognized as an accomplished scientist during her time, and her research and observations on sunspots, Aurora Borealis and comets were met with high regard. She also took on an active role in improving the Berlin Academy of Science, where her husband served as the principal astronomer.

But years later the Academy turned on her. While serving as an assistant to her son at the Berlin Observatory, Academy members complained she took on too prominent of a role and forced her into retirement ending her astronomy career in 1716, aged 46.

Chinese-American physicist Chien-Shiung Wu is credited with disproving one of the basic laws of physics, called conservation of parity. Prior to Wus work, the laws of physics stated that all objects and their mirror images behaved in the same way, symmetrically, meaning that nature could not distinguish between right and left. Wus breakthrough research revealed that during the process of radioactive decay, decaying identical nuclear particles didnt always behave symmetrically.

She also worked on the Manhattan Project, helping develop the process for separating uranium metal and developing better instruments to measure nuclear radiation.

In 1973, Wu became the first woman to lead the American Physical Society, and in 1975 she received the National Medal of Science. Her book Beta Decay remains a standard textbook for nuclear physics students.

The-CNN-Wire & 2020 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.

Go here to see the original:
The heroines STEM: Ten women in science you should know - East Bay Times

Faith and Reason in the Buckeye State – National Catholic Register

Francisco de Zurbarn (1598-1664), St. Thomas Aquinas

The natural sciences show how the world works, but sacred science shows how to reach Heaven.

Recently, the Ohio legislature debated the relationship between faith and reason with HB 164. It is called the Ohio Student Religious Liberties Act of 2019. It passed the House in a 61-31 vote and is now on its way to the state Senate. Critics have argued that HB 164 allows students to be scientifically wrong, as long as they are religiously right. Proponents of the bill have stated that it is about protecting students religious freedom: such as being able to pray on school grounds and citing Scripture in written assignments.

Ohio introduced another bill, HB 182, in November 2019, which would keep insurance companies from covering abortions. However, it also requires doctors to re-implant ectopic pregnancies, though no such procedure exists. Republican State Rep. John Becker admitted in a May 2019 interview with the Cincinnati Enquirer that when he drafted the bill, he did not consult with doctors.

Both these bills portray faith and reason as naturally at odds with each other. Fideism is faith alone, even if it is irrational. On the other hand, rationalism worships the Goddess of Reason while dismissing faith as mythical superstition. They represent two extremes in analysis.

The remedy is the Angelic Doctor, whose feast day is Jan. 28.

At the University of Naples, St. Thomas Aquinas enthusiastically studied theology and philosophy. His mentor, St. Albert the Great, taught him science. The current furor in Ohio calls to mind Aquinas wise words in the Summa Theologiae, Since Holy Scripture can be explained in a multiplicity of senses, one should adhere to a particular explanation, only in such measure as to be ready to abandon it, if it be proved with certainty to be false; lest Holy Scripture be exposed to the ridicule of unbelievers and obstacles be placed to their believing.

The Angelic Doctor, who taught at the University of Paris, followed in the footsteps of St. Paul, who appealed to the philosophers reason when he preached in Athens (Acts 17:16-33). As a voracious reader, Aquinas drew on the wisdom of Athens in the writings of Aristotle, along with the Jewish and Muslim philosophers Maimonides and Avicenna. In his lifetime, he mirrored the narrator of the Book of Wisdom, who says (Wisdom 8:2-3), I loved her (divine wisdom) and sought her from my youth, and I desired to take her for my bride, and I became enamored of her beauty. She glorifies her noble birth by living with God, and the Lord of all loves her.

The opening question of Summa Theologiae is whether any science is necessary for humanity other than philosophical science derived from reason. St. Thomas Aquinas answers, It was necessary for mans salvation that there should be a knowledge revealed by God besides philosophical science built up by human reason. Firstly, indeed, because man is directed to God, as to an end that surpasses the grasp of his reason.

He continues, Even as regards those truths about God which human reason could have discovered, it was necessary that man should be taught by a divine revelation.

For Aquinas, reason and the intellect are good, but not everything. The natural sciences show how the world works, but sacred science shows how to reach Heaven. He does not dismiss human reason. Reason complements divine revelation.

While some of Aquinas scientific views are questionable (such as the Earth remaining stationary), he was open-minded and willing to learn. St. Albert the Great instilled in him a healthy curiosity. Aquinas believed in the importance of dogma but was not dogmatic.

The Ohio bills currently subject to debate risk putting faith at odds with science and reason. When Rep. Becker wrote a May 2019 op-ed for the Cincinnati Enquirer, saying, Even if the medical journals are wrong and HB 182 allows insurance coverage for a procedure that does not yet exist, why is that a problem? ... This bill is forward-looking regarding medical advancements. Unsurprisingly, the media used Rep. Beckers op-ed to further the portrayal of pro-life legislators as ignorant, cruel men who are clueless about the female reproductive system. It contrasts with Aquinas mentor, St. Albert the Great, whose studies in embryology advanced beyond Aristotle. Faith means engagement with reason, rather than detachment from it. Aquinas opens his Summa Contra Gentiles, saying, Now all of human pursuits, that of wisdom is the most sublime, the most profitable, the most delightful.

Both theSumma Theologiae and Summa Contra Gentiles argue that God is truth, according to faith and reason. Aquinas, with his five proofs, shows that Aristotles Prime Mover and the biblical God are one. Faith enriches reason with divine revelation, while reason keeps faith from being blind and mythical.

The current debates in the Ohio legislature demonstrate the necessity for reasonable faith and faithful reason. Aquinas, like St. Paul, defended natural law that is written on their hearts (Romans 2:15).

In the Summa Theologiae, Aquinas declares, The natural law is a participation of the eternal law and therefore endures without change, owing to the unchangeableness and perfection of the Divine Reason, the Author of nature. For Aquinas, God was not only the God of Abraham, Isaac and Jacob, but Natures Author.

The Angelic Doctors philosophical journey inspired him to say, For perfect happiness the intellect needs to reach the very Essence of the First Cause. And thus it will have its perfection through union with God as with that object, in which alone mans happiness consists.

As Our Lord told the Samaritan woman at the well (John 4:23-24), The hour is coming, and now is, when the true worshipers will worship the Father in spirit and truth, for such the Father seeks to worship Him. God is spirit, and those who worship Him must worship in spirit and truth.

See original here:
Faith and Reason in the Buckeye State - National Catholic Register

In Vitro Fertilization Market 2019: Industry Analysis and Detailed Profiles of Top Industry Players AMP Center St Roch, AVA International Clinic…

The following aspects are kept into view while formulating this Global In Vitro Fertilization Market report and include the market type, organization size, availability on-premises, end-users organization type, and availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa. This report also discusses what technologies need to be worked on in order to incentivize future growth, the effects they will have on the market, and how they can be used. Analysis of upstream raw materials, downstream demand and current market dynamics is also performed here. This Global In Vitro Fertilization Market report provides an overview of the ABC industry which is gaining momentum in the last few years.

Global In Vitro Fertilization Market is expected to reach USD 847.8 billion by 2025, from USD 465.2 billion in 2017 growing at a CAGR of 10.0 % during the forecast period of 2018 to 2025. The upcoming market report contains data for the historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Global In Vitro Fertilization Market,By Product (Reagents, Equipment),Type of Cycle (Fresh Non-Donor IVF Cycles, Frozen Non-Donor IVF Cycles, Frozen Donor IVF Cycles, Fresh Donor IVF Cycles), End User (Hospitals & Research Laboratories, Cryobanks ),Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Major Market Competitors/Players:

Some of the major players operating in global in- vitro fertilization market are Groupe Clinique Ambroise Par, amedes MVZ Cologne GmbH, AMP Center St Roch, AVA International Clinic Scanfert, Bangkok IVF center, Betamedics, Biofertility Center, Bloom Healthcare, Bourn Hall Fertility Center, , Cardone & Associates Reproductive Medicine & Infertility, The Center for Advanced Reproductive Services, Chelsea and Westminster Hospital NHS Foundation Trust, Cloudnine Fertility, Conceptions Reproductive Associates of Colorado, Cyprus IVF Centre, Dansk Fertilitetsklinik, EUVITRO S.L.U., , Lieff Cabraser Heimann & Bernstein, LLP, Fertility First, IVF Centers Prof. Zech, Flinders Reproductive Medicine Pty Ltd, Genea Oxford Fertility Limited, IVF Spain, IVI Panama, KL Fertility & Gynaecology Centre, Lifesure Fertility and Gynaecology centre, Manipal Fertility, , Medfem Fertility Clinic, Monash IVF, OVA IVF Clinic Zurich, Procrea, RAPRUI S.r.l., SAFE FERTILITY CENTER, SANNO HOSPITAL, SIRM Fertility Clinics, Stork IVF Klinik, ARC-STER S.r.l., The Montreal Fertility Center, Thomson Medical Centre, TRIO Fertility, Virtus Health, VivaNeo, Die Kinderwunsch and among others.

Competitive Analysis:

The global In- Vitro Fertilization market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of In- Vitro Fertilization market for global, Europe, North America, Asia Pacific and South America.

Market Definition:

In vitro fertilization is a procedure in which egg from women ovary are removed and after that the egg is fertilized with a sperm in a laboratory procedure, and then the fertilized egg is transfered into the women uterus. In vitro fertilization is used in the management of female infertility. In 2018, the Cooper Companies was announce that the Cooper Surgical acquired the assets of The Life Global Group and its affiliates which is a leading provider of invitrofertilization devices. In July 2018, Merck launched new product Geri Assess 2.0.This product is useful in automatic detection of embryo and blastocyst development, improving efficiency in assessment.

According to the Centre for Disease Control and Prevention in 2016, approximately 263,577 ART (Assisted Reproductive Technology) cycle was performed in US. As per the Human Fertilization and Embryology Authority in 2016, more than 68,000 IVF treatments were provided in U.K. In 2016 Birth rate from IVF has been increased to 85.0% in U.K. In 2016 around 20000 childrens were born by IVF. As per the published news IVF Success Rates For Fertility Clinics in the United States in 2016 and around 263,577 ART cycle was performed in U.S. Due to the increasing rate of infertility amongst the population, patients are opting the IVF Fertilization which is fuelling the growth of market.

Major Market Drivers and Restraints:

Market Segmentation:

The global In vitro fertilization market is segmented based on product, type of cycle, end user and geographical segments.

Based on product, the market is segmented into reagents, equipment.

Based on reagents, the market is further segmented into embryo culture media, cryopreservation media, sperm processing media, OVUM processing media.

Based on equipment, the market is further segmented into imaging systems, sperm separation systems, cabinets, OVUM aspiration pumps, incubators, micromanipulator systems, gas analysers, laser systems, accessories, cryo systems, anti-vibration tables, witness systems.

Based on type of cycle, the market is segmented into fresh non-donor IVF cycles, frozen non-donor IVF cycles, frozen donor IVF cycles, fresh donor IVF cycles.

Based on end user, the market is segmented into fertility clinics & surgical centers, hospitals & research laboratories, cryobanks.

Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others

Key Developments in the Market:

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:[emailprotected]

Read more:
In Vitro Fertilization Market 2019: Industry Analysis and Detailed Profiles of Top Industry Players AMP Center St Roch, AVA International Clinic...

Study finds unexpected response to estrogen at the single cell level – News-Medical.net

A team led by researchers at Baylor College of Medicine found that not only do individual mammalian cells in a population fail to respond synchronously to estrogen stimulation, neither do individual gene copies, known as alleles. The findings, published in the recent edition of the journal Nucleic Acids Research, also showed that neither the level of estrogen receptor nor its activation status determined asynchronous cellular responses.

However, a small molecule inhibitor of selected estrogen coregulators increased the response of individual alleles to hormone, establishing a previously unrecognized mode of regulation of estrogen-induced gene activation at the single cell level.

Estrogen is a type of steroid hormone that modulates a large number of biological functions, both in males and females, by regulating the activity of hundreds of genes per cell."

Dr. Fabio Stossi, first author, associate professor of Molecular and Cellular Biology and technical director of the Integrated Microscopy Core at Baylor

A great deal is known about how estrogen triggers its effects. It binds to a nuclear transcription factor (estrogen receptor, or ER), which in turn interacts with specific DNA sequences facilitating the recruitment of coregulators that participate in the regulation of gene expression. It was assumed that this process would likely happen simultaneously in all the ER-containing cells in a population that was stimulated with estrogen, but little was known of how actual single cells or individual copies of the same gene responded. Which is why researchers did not anticipate these finding at the single cell level.

"In the current study, we worked with human breast cancer cell lines grown in the lab. Using both molecular and imaging analyses, we determined, at single cell and allele levels, the expression of two well-characterized genes, GREB1 and MYC, whose activity is regulated by estrogen," said corresponding author, Dr. Michael A. Mancini, professor of Molecular and Cellular Biology, and Pharmacology and Chemical Biology at Baylor. Mancini is also the academic director of the long-running Integrated Microscopy Core (IMC) at Baylor and director of the recently-formed GCC Center for Advanced Microscopy and Image Informatics (CAMII), a CPRIT-funded resource across Baylor and the Texas A&M Institute for Bioscience and Technology.

The researchers incubated the cells in the lab and treated them with estrogen. Then they looked at the expression of GREB1 and MYC genes in individual cells, and at the expression of individual alleles in each cell. As expected, they found that estrogen activated GREB1 and MYC genes quickly, within 15 minutes, but there was an unexpected and marked asynchronous response to hormone simulation at both the individual cell and allele levels.

"Our analyses showed that gene activation of cells in a population appeared more random than we expected. In single cells, the response of each copy of the gene was independent from that of its neighboring cells. In some cells, no alleles of the genes were active, whereas cells next to them would have some or all their gene copies active," Stossi said.

Nevertheless, the researchers explained, that although these findings had not been described before in estrogen receptor biology, they were not a complete surprise.

Studies in genetically identical bacteria have shown that, when subjected to the same treatment, not all the bacteria respond the same way. This is called phenotypical heterogeneity.

"We have been interrogating mechanisms of action of ER via state-of-the-art imaging/analysis since the 90's, with continual improvements in our resources as they are developed or when they come to market, but these recent studies have uncovered novel characteristics of estrogen action in mammalian cells for the first time," Mancini said. "Having phenotypical heterogeneity confers an important adaptation strategy to cell populations, whether they are cancerous or normal. If all the cells in a population responded the same way to a harmful stimulus, for instance, by stopping an essential function, then they would not have the capability of surviving. But respond-ing differently may allow some cells to survive."

The next experiments intended to determine what caused asynchronous estrogen-triggered gene activation. Since the imaging and image analysis routines that were developed and used were amenable to the fully automated, high throughput imaging/analysis platforms within the IMC and CAMII, we had a unique opportunity to explore this question.

First, the researchers hypothesized that cells responded differently to estrogen because the number of estrogen receptors per cell varied. They were surprised to find out that the number of the estrogen receptors expressed in cells was not strictly dictating whether a cell was going to activate the target genes. Then, the researchers investigated whether the cellular response to estrogen depended on the activation status of the estrogen receptor using a patient-linked, constitutively-active receptor, but again, they found no correlation.

Next, the researchers explored the possibility that estrogen receptor coregulators were involved in modulating the allele-by-allele response to estrogen. Utilizing the automated high throughput resources of the IMC/CAMII, they tested a collection of small molecule epigenetic inhibitors and identified one, called MS049, an inhibitor of two protein arginine methyltransferases, that markedly increased the expected number of active alleles per cell under estrogen stimulation, in a gene-specific manner.

"For the first time we were able to alter the nature of the estrogenic response at the allele level, indicating that there are pathways that serve as rheostats to maintain variability of response to a stimulus, thus preventing maximal and uniform behavior in a population of cells," Stossi said. "These findings suggested that modifying the activity of coregulators can tweak the variation of allele-by-allele hormonal responses in a gene-specific manner."

The findings provide novel insights into the complex nature of the regulation of gene expression in mammalian cells.

Source:

Journal reference:

Stossi, F., et al. (2020) Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity. Nucleic Acids Research. doi.org/10.1093/nar/gkz1172.

See the rest here:
Study finds unexpected response to estrogen at the single cell level - News-Medical.net

New Partnership Could Lead To An Almost Instant Off-The-Shelf One-Size-Fits-All Cancer Treatment – Forbes

British scientists who announced last week their discovery of a new type of cancer-killing T-cell have entered a partnership with a biotechnology company pioneering the use of Dark Antigens to developT-cell receptor (TCR)-based immunotherapies and off-the-shelf cancer vaccines. The resultthey hopewill be a one-size-fits-all cancer therapy.

Last Monday, scientists at Cardiff University in the UK announced they had identified a new type of killer T-cella T-cell clonethat recognized and killed multiple different types of human cancer, while ignoring healthy, non-cancerous cells. The discovery, researchers said, offers hope of a universal cancer therapy. The researchers reported in Nature Immunology that these T-cells attacked many forms of cancer from all individuals. The T-cell clone killed lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney and cervical cancer.

Less than a week later, the Cardiff researchers have announced they will enter a partnership with Ervaxx to eventually bring their discovery to patients.

Cardiff University Professor Andrew Sewell

The Cardiff University T-cell modulation group, within the Division of Infection and Immunity, studies all areas of T-cell biology including T-cell genetics, molecular biology, protein chemistry, crystallography and cell biology. The group aims to understand the genetic, biochemical and cellular mechanisms that govern T-cell responses in human diseases, such as HIV, EBV, tuberculosis autoimmunity and cancer.

Professor Andrew Sewell with Research Fellow Garry Dolton

Ervaxx is a UK biotechnology company based in London and Oxford, which is pioneering a new approach to developing targeted immunotherapies for treating and preventing cancer. These immunotherapies, including T-cell therapies, are based on new cancer targets (Dark Antigens) that derive from the dark matter of the genome, which are generally silenced in normal tissue but can become selectively activated in cancer.

T-cell therapies for cancer are the latest paradigm in cancer treatments. Current therapies include CAR-T and TCR-T, where immune cells are removed, genetically-modified and returned to a patients blood to seek and destroy cancer cells. Current therapies are personalized to each patient, target only a few types of blood cancer and have not been successful for solid tumors, which make up the vast majority of cancers.

In contrast, the newly discovered cell attaches to a molecule on cancer cells called MR1, which does not vary in humans.So not only would the treatment work for most types of cancer, said Professor Andrew Sewell, an expert in T-cells and a lead author on the study from Cardiff Universitys School of Medicine, but the same approach could be applied in all patients. It is hoped that the approach might eventually be applied as an almost instant off-the-shelf treatment.

The use of HLA-agnostic T-cell receptors has the promise to transform the treatment of common solid tumors that are presently incurable, said Carl June, MD, in reference to the Cardiff research. A leading expert in the delivery of successful T-cell therapies, June is a professor in Immunotherapy in the Department of Pathology and Laboratory Medicine and the director of the Center for Cellular Immunotherapies and of Translational Research in the Abramson Cancer Center of the University of Pennsylvania. As with organ or bone marrow transplants, previously identified cancer-specific T-cells have been suited only to small sections of the population who share specific tissue types, making it difficult to identify and treat the most appropriate patients. This new T-cell appears not to have these limitations, and if this is borne out in clinical testing, and the approach is shown to be safe and efficacious, it could represent a real advance for the field. We need to cure cancer and not turn it in to a chronic disease.

June studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. According to the Parker Institute, his research team published findings in 2011, which represented the first successful and sustained demonstration of the use of gene transfer therapy to treat cancer. Clinical trials utilizing this approach, in which patients are treated with genetically engineered versions of their own T-cells, are now underway for adults with chronic lymphocytic leukemia and adults and children with acute lymphoblastic leukemia. Early results in that group show that 90 percent of patients respond to the therapy, and more recently, trials of this approach have begun for patients with other blood cancers and solid tumors including pancreatic cancer, mesothelioma and the brain cancer glioblastoma. In 2017, it became the United States first FDA-approved personalized cellular therapy for the treatment of cancer.

Still, Sewell cautioned people from becoming overly optimistic too soon about Cardiffs findings. He said while the scientists discovery is potentially game-changing, an actual universal cancer therapy could be years away.I would really like to stress that we have not cured a patientour results were all laboratory based, albeit with patient T-cells and cancer cells. Clearing cancer in a culture dish and clearing it in a patient are two very different things.

When Cardiff researchers injected the new immune cells into mice with a human immune system and a human blood cancer line, the cancers cells were cleared to a level seen with CAR-T cells in the same mouse model, Sewell said. The group further demonstrated that equipping T-cells of skin cancer patients with the new receptor induced them to destroy not only the patients own cancer cells, but also other patients cancer cells in the laboratory, he said.

Cardiff researchers have now discovered T-cells equipped with a new type of T-cell receptor (TCR) which recognizes and kills most human cancer types, while ignoring healthy cells, Cardiff reported in a press release. This TCR recognizes a molecule present on the surface of a wide range of cancer cells as well as in many of the bodys normal cells but, remarkably, is able to distinguish between healthy cells and cancerous ones, killing only the latter.

Though there are various types of T-cells, Sewell said his interest is in killer T-cellsalso called cytotoxic T-cells. Killer T-cells are fascinating as they have the unique ability to see inside other body cells and scan them for anomalies he said. Conventionally, killer T-cells scan the molecular machines inside cells called proteins. A clever system presents bits of all the proteins inside each cell on its surface bound to molecular platforms called HLA [Human Leukocyte Antigen]. Normal, healthy body cells only present bits of normal proteins, and these are ignored by killer T-cells. If a cell is, for instance, infected with a virus, then it will contain some proteins of viral origin and bits of these will be displayed on the surface of the infected cell. Killer T-cells can recognize these protein fragments as foreign. This activates the killer T-cell to destroy the infected body cell and all its contents, including the virus. In this sense, killer T-cells act as a sophisticated seek and destroy weapon.

T-cells attacking cancer.

When cells become cancerous, they change the expression of some proteins and some proteins mutate, Sewell explained. These changes can also be detected by killer T-cells. Successful cancers go to great lengths to hide from killer T-cells, he said. We know that cancer often exploits the safety checkpoints that are built into T-cells to prevent them causing inflammation or autoimmunity. These checkpoints can be thought of as T-cell brakes, and successful cancers are often good at applying these brakes. Recent development of new drugs called checkpoint inhibitors prevents the application of these brakes and can result in complete clearance of some cancers in some people. Research that led to the discovery of checkpoint inhibitors was awarded the Nobel prize for Physiology or Medicine in 2018.

Sewell said the Cardiff teams discovery could mean exciting opportunities for pan-cancer, pan-population immunotherapies not previously thought possible. The research was funded by the Wellcome Trust, Health and Care Research Wales and Tenovus.

Until now, Sewell said, nobody knew this cell existed. He said the teams hypothesis is that the T-cell works by interacting with a molecule called MR1 which, in turn, flags up the distorted metabolism in a cancer cell.

Now that we know that these types of cells exist, we can actively look for others that work by a similar mechanism. Indeed, we have already found similar broadly tumoricidal, HLA-agnostic killer T-cells that see cancers via different surface molecules. The molecules targeted by these cells were also discovered using the CRISPR library approach. CRISPR gene editing has been a real game-changer.

Sewell said the next step will begin with safety testing on further healthy human cell lines in the laboratory. History has shown, he said, that some T-cells could attack things we dont want them to. We have already demonstrated that our new T-cell does not respond to 20 healthy cell types, he said. The human body has many more cell types than this so, as best we can, we need to rule out that this T-cell does not attack any further healthy human cell types. The new MR1-binding receptor has a natural sequence isolated from a healthy donor and thus the likelihood that it will attack healthy tissue is unlikely.

In any event, Sewell said it is important for people to acknowledge that this discovery has not been tested outside of the laboratory and not yet in human beings. It is impossible to reconstitute a whole human body as individual cell types in the laboratory, so after passing an accepted level of safety testing in this way, the next step is a first-in-man trial Sewell said. In order to minimize the risk, it is likely that the first time this type of T-cell is used in man, the T-cells will transiently [impermanently] express the relevant T-cell receptor and be given in low numbers, with escalation from there once safety is demonstrated. This way if there is any autoimmune attack it will be at low level and short-lived, so hopefully do minimal damage.

While Sewell hesitated at giving a timeline for when an actual universal cancer therapy or cure could be expected, he is hopeful that clinical trials may start in the next few years once further laboratory safety testing is completed.

The new collaboration to develop this recent discovery funded by Ervaxxwill support a multi-year research program with Sewells T-cell modulation group at Cardiff University focusing on the discovery and characterization of T-cells and TCRs reactive to cancer-specific antigens and ligands, including Ervaxx proprietary Dark Antigens.

The company has the right to advance resulting candidate T-cell/TCR-based immunotherapeutics and cancer vaccines through development and commercialization, Ervaxx stated in a press release.

Kevin Pojasek, Ervaxx CEO, said the collaboration with the Cardiff University research group shows early but enormous potential for the treatment of cancers. He said the partnership, which follows those with the University of Oxford, University of Cambridge and Johns Hopkins University School of Medicine, reinforces our ambition to collaborate with leading academic institutions and be at the cutting edge of the T-cell immunology field to drive the development of novel off-the-shelf cancer therapies.

In terms of the MR1 finding, when asked if it meant that some people are completely immune to cancer, Sewell said, Possibly. This immune cell could be quite rare, or it could be that lots of people have this receptor, but for some reason it is not activated. We just don't know yet, but we hope that this finding can be exploited and will pave the way for new cancer treatments.

See the original post:
New Partnership Could Lead To An Almost Instant Off-The-Shelf One-Size-Fits-All Cancer Treatment - Forbes

Marketing and Design Coordinator job with The Rockefeller University Press | 410015 – mediabistro.com

Rockefeller University Press (RUP) journals publish groundbreaking research in the life sciences and biomedicine from leading investigators around the world and serve as a valued resource to those engaged in cutting-edge research and who train future generations of scientists. We use the latest technologies and carry out rigorous peer review, applying the highest standards of novelty, mechanistic insight, data integrity, and general interest to fulfill our mission of publishing excellent science.

RUP publishes Journal of Cell Biology (JCB), Journal of Experimental Medicine (JEM), and Journal of General Physiology (JGP) and co-publishes Life Science Alliance (LSA). RUPs nonprofit journals were established by the research community, and editorial decisions and policies continue to be driven by scientists who actively contribute to their fields, appreciate the value of peer review, and desire a better publication experience for all.

We seek a Marketing and Design Coordinator to play an essential role in promoting RUP and its peer-reviewed scientific journals: JCB, JEM, JGP, and LSA.

The Position

Reporting to the RUP Director of Communications and Marketing, you will implement strategies that highlight the impactful research published in the journals and the editorial and publishing policies that benefit the scientific community and provide a best-in-class experience for authors.

Responsibilities include:

Qualifications

How to Apply

RUP is based in New York City and is a department of The Rockefeller University, a leading biomedical research university dedicated to conducting innovative, high-quality research to improve the understanding of life for the benefit of humanity.

We offer a competitive salary, comprehensive benefits, and a collaborative work environment. Please upload a resume and cover letter when submitting an application.

The Rockefeller University is an Equal Opportunity Employer - Minorities/Women/Disabled/Veterans

Original post:
Marketing and Design Coordinator job with The Rockefeller University Press | 410015 - mediabistro.com